Companies
Synopsys Beats Expectations in Q1 Financial Report
Synopsys, Inc. unveiled its first-quarter financial results after Wednesday's market closure, showcasing impressive performance across key metrics. The company reported...
Dutch Bros Exceeds Expectations in Q4 Financial Report
Dutch Bros Inc. (BROS) shares experienced an uptick following the release of their fourth-quarter financial results on Wednesday. The company...
Nvidia Surpasses Expectations with Strong Q4 Results and Optimistic Guidance
Following the close of the market on Wednesday, Nvidia Corp. (NVDA), an AI powerhouse, disclosed its fourth-quarter financial outcomes and...
Rivian’s Quarterly Report: Revenue Exceeds Estimates, EPS Falls Short, and Insights into 2024 Plans
Rivian Automotive (RIVN), the electric vehicle manufacturer, unveiled its fourth-quarter financial results following Wednesday's market closure, offering crucial insights into...
Bausch + Lomb’s Strong Growth Outlook Boosts Stock Amid Losses
Bausch + Lomb Corp (BLCO) experienced a significant surge in its stock value, rising by 15.8%, despite facing deeper losses,...
Prestige Consumer Healthcare Posts Strong Q3 Fiscal 2024 Results
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported robust financial results for its third quarter and first nine months ending December...
Axalta Releases Strong Q4 and Full Year 2023 Results
Axalta Coating Systems Ltd. (NYSE: AXTA) reported robust financial results for the fourth quarter and full year ending December 31,...
I-Mab Shifts Focus; Divests Chinese Operations to Propel U.S. Biotech Ambitions
In a strategic move to bolster its presence in the U.S. biotech landscape, I-Mab (NASDAQ: IMAB), a renowned global biotech...
3M M Modal Fluency for Imaging Clinches 1 Best in KLAS Award for Fourth Consecutive Year
3M Health Information Systems (HIS) proudly announces that its cutting-edge solution, 3M M Modal Fluency for Imaging, has secured the...
Regenxbio’s RGX-121 Trial Achieves Major Milestone in Hunter Syndrome Treatment
Regenxbio Inc. (Nasdaq: RGNX) has announced significant progress in its Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of...
